EMA has received an application for conditional marketing authorisation (CMA) for a COVID-19 vaccine developed by Janssen-Cilag International N.V. EMA’s human medicines committee (CHMP) will assess the vaccine, known as COVID-19 Vaccine Janssen, under an accelerated timetable. The Committee could issue an opinion by the middle of March 2021, provided the company’s data on the vaccine’s efficacy, safety […]
Read More
HERA Incubator to anticipate the threat of COVID-19 variants
Von der Leyen announces the start of HERA Incubator to anticipate the threat of coronavirus variants To prepare Europe for an increased threat of coronavirus variants, the President of the European Commission Ursula von der Leyen announced the start of European bio-defence preparedness plan called “HERA Incubator”. The Health Emergency Preparedness and Response Authority (HERA) Incubator will […]
Read More
Outbreak of Ebola virus disease in Africa
As of 14 February 2021, four cases of Ebola virus disease (EVD), including two deaths, have been reported in the North Kivu province in the eastern part of the Democratic Republic of the Congo (DRC) as well as seven cases in Guinea, including three deaths. On 7 February 2021, the Minister of Health of the […]
Read More
EMA preparing guidance to tackle COVID-19 variants
EMA is developing guidance for manufacturers planning changes to the existing COVID-19 vaccines to tackle the new virus variants. In order to consider options for additional testing and development of vaccines that are effective against new virus mutations, the Agency has requested all vaccine developers to investigate if their vaccine can offer protection against any […]
Read More
COVID-19 Evolution – 2020
This document collects and analyzes the data on the evolution of COVID-19, collected by the Johns Hopkins University and published daily by the European Documentation Center of Almeria during the year 2020. On January 24, 2020 France reported the first case of COVID-19, being the first case, being the first known case of COVID-19 in […]
Read More
EU urges AstraZeneca to explain vaccine delivery delays
▶️ Watch the press conference by Commissioner @SKyriakidesEU on vaccine deliveries and on the export transparency scheme. #StrongerTogether https://t.co/iczvKiAiRm — European Commission 🇪🇺 (@EU_Commission) January 25, 2021 Last Friday, the company AstraZeneca surprisingly informed the Commission and the European Union Member States that it intends to supply considerably fewer doses in the coming weeks than […]
Read More
Commission concludes exploratory talks with Valneva to secure a new potential vaccine
The European Commission concluded exploratory talks with the pharmaceutical company Valneva with a view to purchasing its potential vaccine against COVID-19. The envisaged contract with Valneva would provide for the possibility for all EU Member States to purchase together 30 million doses, and they could further purchase up to 30 million more doses. This finalisation […]
Read More
Torrecárdenas: the only hospital in Andalusia participating in the FOCUS program
After a selection process, Torrecárdenas University Hospital will participate in the implementation of the FOCUS program. The FOCUS program has been underway since 2010 and it aims to provide early diagnosis of infections such as HIV and Hepatitis C in hospitals and health centers. This is possible thanks to the agreement between the Andalusian Health […]
Read More
EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
EMA has received an application for conditional marketing authorisation (CMA) for a COVID-19 vaccine developed by AstraZeneca and Oxford University. The assessment of the vaccine, known as COVID-19 Vaccine AstraZeneca, will proceed under an accelerated timeline. An opinion on the marketing authorisation could be issued by 29 January during the meeting of EMA’s scientific committee for human […]
Read More